the corporate reputation of pharma in 2017 · contents 1 executive summary 9 methodology 14...
TRANSCRIPT
FEEDBACK FROM 1,330 PATIENT GROUPS WORLDWIDE PUBLISHED APRIL 2018
THE CORPORATE REPUTATION OF PHARMA IN 2017 THE PATIENT PERSPECTIVE — GLOBAL EDITION
CONTENTS
1 EXECUTIVE SUMMARY
9 METHODOLOGY
14 PATIENT-GROUP RELATIONSHIPS WITH PHARMA, 2017
18 INDUSTRY-WIDE FINDINGS, 2017 22 RANKINGS OF THE 46 PHARMA COMPANIES, 2017 v. 2016 AMONG PATIENT GROUPS FAMILIAR WITH THE COMPANIES
37 POSITIONING OF THE 46 PHARMA COMPANIES, 2017 v. 2016 AMONG PATIENT GROUPS THAT WORK/PARTNER WITH THE COMPANIES
52 PROFILES OF THE 46 COMPANIES, 2017
APPENDICES
I. WHAT 9 PHARMACEUTICAL COMPANIES SAY ABOUT THEIR
PATIENT-ORIENTED ACTIVITIES, 2017-2018
II. PROFILES OF RESPONDENT PATIENT GROUPS, 2017
TABLES AND CHARTS
2 THE PHARMA INDUSTRY’S CORPORATE REPUTATION, 2011-2017 (ACCORDING TO PATIENT GROUPS)
3 PHARMA-INDUSTRY REPUTATION AT BEING INNOVATIVE, 2011-2017 (ACCORDING TO PATIENT GROUPS)
5 COMPANIES SHOWING THE BIGGEST IMPROVEMENT IN OVERALL RANKINGS FOR CORPORATE
REPUTATION, 2017 v. 2016 (ACCORDING TO PATIENT GROUPS FAMILIAR WITH THE COMPANY)
5 COMPANIES SHOWING THE BIGGEST IMPROVEMENT IN OVERALL POSITIONINGS FOR CORPORATE
REPUTATION, 2017 v. 2016 (ACCORDING TO PATIENT GROUPS THAT WORK/PARTNER WITH THE
COMPANY)
6 COMPANY NET PROMOTER SCORE, 2017—COMPARED WITH COMPANY POSITION IN THE LEAGUE TABLE
(ACCORDING TO PATIENT GROUPS THAT WORK WITH/PARTNER WITH THE COMPANY)
7 COMPANY AVERAGE NET PROMOTER SCORE, 2017—PLOTTED AGAINST COMPANY POSITION IN THE
PATIENT-GROUP-PARTNER LEAGUE TABLE
11 PERCENTAGE OF PATIENT GROUPS WORKING WITH EACH COMPANY, 2017—AS A PROPORTION OF
PATIENT GROUPS FAMILIAR WITH THE COMPANY
12 THE 12 INDICATORS OF CORPORATE REPUTATION USED IN THE 2017 PATIENT-GROUP SURVEY
13 PERCENTAGE OF PATIENT GROUPS STATING THAT “NONE” OF THE 46 COMPANIES WERE “BEST” FOR
EACH INDICATOR (INDICATOR BY INDICATOR)
15 LEVELS OF FAMILIARITY OF PATIENT GROUPS WITH 46 COMPANIES, 2017 (AND LEVELS OF PATIENT-
GROUP PARTNERSHIPS WITH THE PHARMA COMPANIES)
16 LEVELS OF FAMILIARITY OF PATIENT GROUPS WITH 46 COMPANIES, 2017—RANKED HIGH TO LOW
16 PHARMA COMPANIES AND LEVELS OF PATIENT-GROUP PARTNERSHIPS, 2017—RANKED HIGH TO LOW
17 TYPES OF RELATIONSHIPS THAT PATIENT GROUPS HAVE WITH PHARMACEUTICAL COMPANIES, 2017
19 THE CORPORATE REPUTATION OF THE PHARMACEUTICAL INDUSTRY, 2017 v. 2016—COMPARED WITH
EIGHT OTHER HEALTHCARE SECTORS
19 THE CORPORATE REPUTATION OF THE PHARMACEUTICAL INDUSTRY, 2011-2017
20 PERCEPTIONS OF THE EFFICACY OF THE PHARMACEUTICAL INDUSTRY AT VARIOUS ACTIVITIES OF IMPORTANCE TO PATIENT GROUPS, 2017 [CHART AND TABLE]
21 PERCEPTIONS OF THE EFFICACY OF THE PHARMACEUTICAL INDUSTRIES AT VARIOUS ACTIVITIES IMPORTANT TO PATIENT GROUPS, 2011-2017
22 RANKINGS OF INDIVIDUAL PHARMA COMPANIES, 2017 v. 2016 (ACCORDING TO PATIENT GROUPS FAMILIAR WITH THE COMPANY)
37 POSITIONINGS OF INDIVIDUAL PHARMA COMPANIES, 2017 v. 2016 (ACCORDING TO PATIENT GROUPS THAT WORK/PARTNER WITH THE COMPANY)
TABLES AND CHARTS, continued
52 PROFILES OF THE 46 COMPANIES, 2017
CHARTS AND TABLES FOR EACH OF THE 46 COMPANIES:
Number of patient groups claiming familiarity with the company, 2017.
Number of patient groups saying that they had a working relationship with the company, 2017.
Company scores among patient groups familiar with the company, and which worked with the company, for each of the 12 indicators of corporate reputation, 2017.
Percentage of the patient groups that worked with the company, but which also worked with other companies, 2017.
Profile of respondent patient groups familiar, and working, with the company, 2017: country headquarters; specialties; geographic remit; and types of relationships.
Snapshot view: where the company sits in the corporate rankings for each of the 12 indicators (in the higher, the middle, or the lower tier), 2017.
Overall rankings for the company according to patient groups familiar with the company, 2017.
Overall positionings for the company according to patient groups that work with the company, 2017.
Company rankings for each of the 12 indicators according to patient groups familiar, or working, with the company, 2017 v. 2016.
The company’s average scores across all indicators of corporate reputation, 2011-2017.
The company’s net promoter score, 2017.
TABLES AND CHARTS, continued
Page COMPANY PROFILE
54 ABBVIE
56 ACORDA THERAPEUTICS
58 ALLERGAN
60 ALMIRALL
62 AMGEN
64 ASTELLAS PHARMA
66 ASTRAZENECA
68 BAYER
70 BIAL
72 BIOGEN
74 BOEHRINGER INGELHEIM
76 BRISTOL-MYERS SQUIBB
78 CELGENE
80 CHIESI FARMACEUTICI
82 CSL BEHRING
84 DAIICHI SANKYO
86 EISAI
88 ELI LILLY (LILLY)
90 FERRING
92 GEDEON RICHTER
94 GILEAD SCIENCES
96 GRIFOLS
98 GRÜNENTHAL
100 GSK
102 IPSEN
104 JANSSEN
106 LEO PHARMA
108 LUNDBECK
110 MENARINI
112 MERCK & CO
114 MERCK KGaA
116 NOVARTIS
118 NOVO NORDISK
120 OCTAPHARMA
122 OTSUKA
124 PFIZER
126 PIERRE FABRE LABORATORIES
128 ROCHE
130 SANOFI
132 SERVIER
134 SHIRE
136 TAKEDA
138 TEVA
140 UCB
142 VERTEX PHARMACEUTICALS
144 ViiV HEALTHCARE
CONTACT DETAILS: PATIENTVIEW LTD REGISTERED OFFICE: ONE FLEET PLACE, LONDON, EC4M 7WS, UK TEL: +44-(0)1547-520-965 EMAIL: [email protected] REGISTERED IN ENGLAND, NUMBER: 3944382 DATA PROTECTION REGISTRATION NUMBER: Z7133076 VAT REGISTRATION NUMBER: GB-760-985-885
COPYRIGHT © 2018 PATIENTVIEW LTD ALL RIGHTS RESERVED THIS BOOKLET IS THE PROPERTY OF PATIENTVIEW, AND NO PART MAY BE REPRODUCED WITHOUT PERMISSION, OR PASSED ON TO ANY THIRD PARTY WITHOUT THE PERMISSION OF PATIENTVIEW